With Expert’Biome, Lallemand Health Solutions aims to support partners in their development of next-generation strains by offering comprehensive services in the health industry
Lallemand Health Solutions is strengthening its strategic position in the microbiome field through contract development and manufacturing operations, with the launch of Expert’Biome CDMO by Lallemand.
With Expert’Biome, Lallemand Health Solutions aims to support partners in their development of next-generation strains by offering comprehensive services in the health industry. These services include strain research and development, bioprocesses scaling, drug manufacturing, and other production steps.
Jérôme Panes, President and General Manager at Lallemand Health Solutions emphasises the strategic importance of this development, stating, “Expert’Biome leverages 90 years of know-how, from research and development to pilot-scale production and commercial manufacturing for microorganisms, and uses cutting-edge technologies and innovative scientific approaches to pioneer next-generation strains. Our manufacturing facilities have adhered to the highest quality standards for several decades, including cGMP Pharma for investigational and commercial biological products, internationally recognised accreditations and licenses. We are committed to securing a leading position in this booming market.” He also adds, “Laurie Rey, with a PhD in Molecular Biology, has been appointed as Head of Expert’Biome Business Development. She will bring her experience, cumulated in the last decade, in partnership development in the life sciences and biotechnology sectors. As the main point of contact for this activity, she will ensure streamlined project execution”.
Laurie Rey declares: “The microbiome is taking on new significance, as evidenced by increased research and development and commercial success. Between 2021 and 2023, there has been a 24 per cent increase in ongoing development trials worldwide, along with an 18 per cent increase in countries with products in development targeting the microbiome. Over the past two years, several regulatory approvals have paved the way for next-generation microbiome strains as potential drugs to improve well-being in various health areas.
